UBS Group’s Bone Biologics Corp Warrants BBLGW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.1K | Buy |
513
+91
| +22% | +$1.5K | ﹤0.01% | 9094 |
|
|
2026
Q1 | $5.63K | Buy |
422
+122
| +41% | +$2.9K | ﹤0.01% | 8763 |
|
|
2025
Q4 | $3K | Buy |
300
+157
| +110% | +$2.43K | ﹤0.01% | 9146 |
|
|
2025
Q3 | $1.14K | Hold |
143
| – | – | ﹤0.01% | 9423 |
|
|
2025
Q2 | $1.14K | Hold |
143
| – | – | ﹤0.01% | 9669 |
|
|
2025
Q1 | $450 | Buy |
143
+103
| +258% | +$6.23K | ﹤0.01% | 9773 |
|
|
2024
Q4 | $1.6K | Hold |
40
| – | – | ﹤0.01% | 9197 |
|
|
2024
Q3 | $46 | Buy |
+40
| New | +$2.68K | ﹤0.01% | 9244 |
|
|
2023
Q4 | – | Sell |
-61
| Closed | -$846 | – | 9304 |
|
|
2023
Q3 | $846 | Buy |
+61
| New | +$299 | ﹤0.01% | 8247 |
|
|
2023
Q2 | – | Sell |
-8
| Closed | -$10 | – | 8916 |
|
|
2023
Q1 | $10 | Buy |
+8
| New | +$11 | ﹤0.01% | 9458 |
|
|
2022
Q4 | – | Sell |
-143
| Closed | – | – | 10725 |
|
|
2022
Q3 | $0 | Hold |
143
| – | – | ﹤0.01% | 10325 |
|
|
2022
Q2 | $1K | Sell |
143
-220
| -61% | -$1.64K | ﹤0.01% | 9819 |
|
|
2022
Q1 | $4K | Buy |
363
+210
| +137% | +$2.8K | ﹤0.01% | 9269 |
|
|
2021
Q4 | $3K | Buy |
+153
| New | +$3.82K | ﹤0.01% | 9645 |
|
Other funds holding BBLGW
UBS Group's BBLGW Position: Q2 2026 in Review
UBS Group increased its Bone Biologics Corp Warrants (BBLGW) stake by 22% in Q2 2026, buying an estimated $1.5K and bringing the position to 513 shares worth $4.1K. The position accounts for ﹤0.01% of the portfolio, ranked #9094.
UBS Group first reported a position in BBLGW in Q4 2021 and has held it in 14 quarters since. The position peaked at $5.63K in Q1 2026. 2 funds tracked by Wall St. Rank hold BBLGW as of Q2 2026.
- UBS Group held 513 shares of Bone Biologics Corp Warrants worth $4.1K as of Q2 2026.
- UBS Group bought 91 Bone Biologics Corp Warrants shares in Q2 2026, an estimated $1.5K.
- Bone Biologics Corp Warrants made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9094 holding.
- UBS Group first reported a position in Bone Biologics Corp Warrants in Q4 2021 and has held it in 14 quarters since.
- UBS Group's Bone Biologics Corp Warrants position peaked at $5.63K in Q1 2026.
- 2 funds tracked by Wall St. Rank held Bone Biologics Corp Warrants as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.